ORG Wealth Partners LLC Buys Shares of 3,961 Pfizer Inc. (NYSE:PFE)

ORG Wealth Partners LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,961 shares of the biopharmaceutical company’s stock, valued at approximately $115,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Olistico Wealth LLC purchased a new position in shares of Pfizer in the 2nd quarter worth $25,000. MFA Wealth Advisors LLC purchased a new position in shares of Pfizer in the second quarter worth approximately $29,000. Quarry LP bought a new stake in Pfizer during the second quarter valued at approximately $31,000. Creekmur Asset Management LLC bought a new position in Pfizer in the fourth quarter worth approximately $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its stake in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Wells Fargo & Company lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Trading Down 0.3 %

PFE stock opened at $29.08 on Tuesday. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm has a fifty day moving average price of $29.02 and a 200 day moving average price of $28.40. The firm has a market cap of $164.78 billion, a PE ratio of -484.67, a price-to-earnings-growth ratio of 1.30 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the firm earned $0.67 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.78%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.